Nephrocare Health Services Ltd (NEPHROPLUS)
₹673.10
Mkt cap
₹6,769 Cr
P/E ratio
90.40
P/B
6.06
Div yield
0.00%
ROE
8.83%
ROCE
15.30%
EPS (TTM)
₹7.45
Book value
₹111
52W range
449–751
Sector
Healthcare
Incorporated in 2010, Nephrocare Health Services Ltd. provides end-to-end dialysis care through a wide network of clinics across India and select international markets. [1]
Health check
Mixed
ValuationExpensive
ProfitabilityAverage
GrowthHigh
TechnicalsNeutral
52-week range
−10.41% from high₹673
₹449+49.86% from low₹751
Current
₹673.10
Prev close
₹676.00
Day
−0.43%
Price performance
1D
−0.43%
1W
+7.05%
1M
+2.30%
3M
+26.15%
6M
+36.05%
1Y
—
YTD
+41.88%
Financials
FRevenue, profit & margin
P/E ratio
90.4×
NEPHROPLUS is 91% above the sector median of 47.4×
NEPHROPLUS90.4×
Sector median47.4×
| Dec 2024 | Mar 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Trend | |
|---|---|---|---|---|---|---|
| Sales | 197 | 219 | 246 | 260 | 266 | |
| Expenses | 153 | 168 | 182 | 199 | 215 | |
| Operating Profit | 44 | 51 | 64 | 61 | 51 | |
| OPM % | 22% | 23% | 26% | 23% | 19% | |
| Other Income | 5 | 4 | 4 | 3 | 12 | |
| Interest | 5 | 6 | 45 | 6 | 3 | |
| Depreciation | 18 | 19 | 23 | 22 | 26 | |
| Profit before tax | 26 | 30 | -1 | 36 | 33 | |
| Tax % | 24% | 17% | 1,427% | 11% | 9% | |
| Net Profit | 20 | 25 | -9 | 32 | 30 | |
| EPS in Rs | 96.50 | 119.30 | -5.24 | 3.21 | 3.03 | |
| Raw PDF |
Earnings
EResults dates & reactionsNext results
11 Aug '26
Fresh quarters land in the Financials table above, tagged NSE until screener catches up.
No reaction history yet.
No quarterly filings ingested yet.
Corporate actions
CLast 6 monthsNo recent corporate actions
Dividends, splits, and bonuses in the last six months show up here.
Shareholding
Sas of Jun 202663.85%Promoter
Promoters63.85%
FIIs8.78%1.16
DIIs9.05%0.41
Public18.30%0.74
Ownership trend
Peers
P7 companiesValuation vs quality
P/E × ROCE · bubble = market cap| Name | CMP | P/E | Mkt Cap | Div Yld | NP Qtr | Qtr Profit Var | Sales Qtr | Qtr Sales Var | ROCE |
|---|---|---|---|---|---|---|---|---|---|
| Dr Lal Pathlabs | ₹1,759.20 | 52.45 | 29,491 | 0.80% | 171 | +28.02% | 798 | +19.10% | 28.00% |
| Vijaya Diagnost. | ₹1,313.90 | 78.23 | 13,533 | 0.15% | 48 | +34.56% | 219 | +26.63% | 21.29% |
| Metropolis Healt | ₹570.25 | 60.20 | 11,823 | 0.35% | 51 | +74.43% | 425 | +22.99% | 17.77% |
| Thyrocare Tech. | ₹564.25 | 49.69 | 8,981 | 1.65% | 51 | +34.06% | 240 | +24.34% | 35.38% |
| Nephrocare Health Services | ₹673.10 | 90.37 | 6,769 | 0.00% | 30 | +22.11% | 266 | +21.18% | 15.34% |
| Krsnaa Diagnost. | ₹544.80 | 17.21 | 1,767 | 0.50% | 43 | +105.89% | 173 | −0.93% | 12.70% |
| Suraksha Diagno. | ₹252.95 | 40.93 | 1,317 | 0.20% | 6 | −15.02% | 81 | +25.07% | 16.97% |
| Median: 14 Co. | ₹554.52 | 47.42 | 1,235 | 0.07% | 14 | +25.80% | 153 | +22.09% | 22.28% |
Filings
DConcall transcripts6
Credit ratings3
Announcements5
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation 15h - NephroPlus Q1FY27 earnings call scheduled for August 12, 2026 at 10:00 A.M. IST.Board Meeting Intimation for The Company Has Informed BSE That The Meeting Of The Board Is Scheduled On 11/08/2026 ,Inter Alia, To Consider And Approve The Unaudited Standalone And Consolidated Financial Results Of The Company For The Quarter Ended June 30, 2026. 15h - Board meeting on August 11, 2026 to approve Q1 FY27 unaudited standalone and consolidated results.Announcement under Regulation 30 (LODR)-Newspaper Publication 17 Jul - Newspaper Publication regarding Notice on 17th Annual General Meeting and information on remote e-voting.Disclosure Under Regulation 36(1)(B) Of SEBI (LODR) Regulations, 2015 (''SEBI Listing Regulations'') 16 Jul - AGM scheduled for August 12, 2026; annual report and notice dispatched to shareholders.Notice Of 17Th Annual General Meeting Of The Company To Be Held On Wednesday, August 12, 2026. 16 Jul - 17th AGM on August 12, 2026; members to vote on financials, director reappointment, ESOP 2026, and promoter incentive.